Multi-kinase inhibitor
Elzovantinib for Solid Tumors
Recruiting1 awardPhase 1
Irvine, California
This trial is testing a new cancer drug to see if it is safe and effective. The study will first test increasing doses of the drug to see what the safe range is. Then, the study will expand to test the drug's effectiveness against different types of cancer.
Monoclonal Antibodies
Sacituzumab Govitecan + Capecitabine for Gastrointestinal Cancer
Recruiting1 awardPhase 1
Detroit, Michigan
This trial is testing a new combination of drugs, sacituzumab govitecan and capecitabine, for patients with advanced gastrointestinal cancers that have not responded to standard treatments. Researchers
Alkylating agents
Immunotherapy + Chemoradiation for Gastric Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing a combination of immunotherapy drugs, chemo, and radiation to treat gastric cancer. The hope is that the immunotherapy will help the body's immune system attack the cancer, and that the combination of treatments will be more effective than any one treatment alone.
Popular Filters
Trials for Adenocarcinoma Patients
Monoclonal Antibodies
SGN-CEACAM5C for Advanced Cancers
Recruiting1 awardPhase 1
Grand Rapids, Michigan
This trial is testing a new drug called SGN-CEACAM5C for patients with hard-to-treat solid tumors that have either returned or didn't respond to standard treatments. The drug targets cancer cells and kills them. The study will determine the safe dosage and effectiveness of the drug.
Cancer Vaccine
EO-3021 for Gastrointestinal Cancer
Recruiting1 awardPhase 1
Nashville, Tennessee
This trial is testing a new treatment for adult patients with solid tumors that have a specific marker called CLDN18.2. The treatment aims to find and destroy cancer cells with this marker. This approach helps target the cancer more precisely without affecting normal cells. CLDN18.2 has been identified as a promising target for cancer therapy, particularly in gastric cancer.
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Trials for Gastric Adenocarcinoma Patients
Monoclonal Antibodies
SGN-CEACAM5C for Advanced Cancers
Recruiting1 awardPhase 1
Grand Rapids, Michigan
This trial is testing a new drug called SGN-CEACAM5C for patients with hard-to-treat solid tumors that have either returned or didn't respond to standard treatments. The drug targets cancer cells and kills them. The study will determine the safe dosage and effectiveness of the drug.
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Trials for Metastatic Patients
Monoclonal Antibodies
SGN-CEACAM5C for Advanced Cancers
Recruiting1 awardPhase 1
Grand Rapids, Michigan
This trial is testing a new drug called SGN-CEACAM5C for patients with hard-to-treat solid tumors that have either returned or didn't respond to standard treatments. The drug targets cancer cells and kills them. The study will determine the safe dosage and effectiveness of the drug.
Cancer Vaccine
EO-3021 for Gastrointestinal Cancer
Recruiting1 awardPhase 1
Nashville, Tennessee
This trial is testing a new treatment for adult patients with solid tumors that have a specific marker called CLDN18.2. The treatment aims to find and destroy cancer cells with this marker. This approach helps target the cancer more precisely without affecting normal cells. CLDN18.2 has been identified as a promising target for cancer therapy, particularly in gastric cancer.
Monoclonal Antibodies
MK-7684A for Advanced Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Trials for HER2 Positive Patients
Monoclonal Antibodies
Amivantamab for Esophageal Cancer
Recruiting1 awardPhase 2
Basking Ridge, New Jersey
This trial is testing a drug called amivantamab to see if it can treat esophagogastric cancer with specific genetic changes. The drug works by blocking proteins that help cancer cells grow. Researchers also want to know if the drug is safe and causes only mild side effects.
Chemotherapy
T-DXd Combinations for Stomach Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial is investigating the safety and preliminary effectiveness of a new cancer drug, trastuzumab deruxtecan (T-DXd), for treating HER2-positive gastric and esophageal cancers. The study will also look at whether T-DXd is more effective when given in combination with other cancer treatments.
Trials for PD-L1 Positive Patients
Monoclonal Antibodies
Rilvegostomig Combination for Stomach Cancer
Recruiting2 awardsPhase 3
Duarte, California
"This trial is studying the effectiveness and safety of a new drug called rilvegostomig in combination with other medications for treating a specific type of stomach cancer. They will compare this new combination
Chemotherapy
Immunotherapy Combinations for Esophageal Cancer
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial tests a combination of chemotherapy and immunotherapy in patients with advanced gastric and esophageal cancers. It aims to see if this combination is safe and effective, especially for those who haven't responded to other treatments or haven't been treated before. Combination therapies involving chemotherapy and immunotherapy have shown promising results in initial clinical trials for cancer treatment.
Phase 3 Trials
Antimetabolites
Chemotherapy + Radiotherapy for Esophageal and Gastric Cancer
Recruiting2 awardsPhase 3
Anchorage, Alaska
This trial is studying how well adding radiotherapy to the usual chemotherapy treatment works compared to the usual treatment alone in treating patients with esophageal and gastric cancer.
Chemotherapy
Bemarituzumab + Chemotherapy for Stomach Cancer
Recruiting1 awardPhase 3
Anchorage, Alaska
This trial is testing whether adding bemarituzumab to standard chemotherapy helps patients live longer. It targets patients whose tumors have a specific marker (FGFR2b). The treatment works by blocking a protein that helps cancer cells grow.
Monoclonal Antibodies
Rilvegostomig Combination for Stomach Cancer
Recruiting2 awardsPhase 3
Duarte, California
"This trial is studying the effectiveness and safety of a new drug called rilvegostomig in combination with other medications for treating a specific type of stomach cancer. They will compare this new combination
Trials With No Placebo
Monoclonal Antibodies
SGN-CEACAM5C for Advanced Cancers
Recruiting1 awardPhase 1
Grand Rapids, Michigan
This trial is testing a new drug called SGN-CEACAM5C for patients with hard-to-treat solid tumors that have either returned or didn't respond to standard treatments. The drug targets cancer cells and kills them. The study will determine the safe dosage and effectiveness of the drug.
Cancer Vaccine
EO-3021 for Gastrointestinal Cancer
Recruiting1 awardPhase 1
Nashville, Tennessee
This trial is testing a new treatment for adult patients with solid tumors that have a specific marker called CLDN18.2. The treatment aims to find and destroy cancer cells with this marker. This approach helps target the cancer more precisely without affecting normal cells. CLDN18.2 has been identified as a promising target for cancer therapy, particularly in gastric cancer.
Monoclonal Antibodies
MK-7684A for Advanced Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.